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Sampling Serum in PatientsWith Vitiligo toMeasure
Disease Activity in the Skin
Mehdi Rashighi, MD; John E. Harris, MD, PhD
In this issueofJAMADermatology,Speeckaertandcolleagues1
report that levels of the soluble CD25 and CD27 molecules
(sCD25 and sCD27) are elevated in the serum of patients with
active vitiligo compared with patients with stable disease. In
addition, sCD25 levels were
found to be significantly
lower in the serum of pa-
tientsbeing treatedwith topi-
cal immunosuppressants (including steroids and calcineurin
inhibitors) andtheserumlevelof sCD27wassignificantly lower
in patients with recent repigmentation, suggesting a poten-
tial to use these as biomarkers to monitor treatment re-
sponses. Interestingly, the authors continued to prospec-
tively study a relatively large number of participants and
demonstrated that serumlevelsofboth sCD25andsCD27were
associated with disease progression during follow-up. These
important findings suggest that monitoring of these markers
in the serum of patients with vitiligo may provide a glimpse
into what is happening in the skin, a process that is not obvi-
ous by simple observation in vitiligo, in contrast to more in-
flammatory diseases.
CD25 is theα chain subunit of theheterotrimeric interleu-
kin 2 (IL-2) receptor, which is expressed on the surface of
activated T cells. Interleukin 2 is a cytokine with pleiotropic
immune functions, largely known for its role in both inflam-
mation and induction of immune tolerance,2 as it is a growth
factor for effector T cells that promote inflammation, as well
as for regulatory T cells that suppress inflammation. Soluble
CD25 results from the proteolytic cleavage of the IL-2 recep-
tor on activated T cells and is reportedly elevated in the se-
rum and plasma of patients with several lymphoproliferative
and autoimmune diseases.3 A recent study suggested that
sCD25might act as a decoy receptor to sequester local IL-2 in
T cell–infiltrated peripheral tissue, and therefore diminish
IL-2–mediated immune suppression, although its functional
role in immune responses is still largely unclear.3 Regardless,
the sCD25 level is remarkably stable in the serum of healthy
individuals, supporting its use as a clinical biomarker for dis-
ease activity in inflammatory diseases.4
CD27 is a type I transmembraneproteinandmemberof the
tumornecrosis factor receptor superfamily that is expressedon
the surface of specific subsets of T cells (among other immune
cells), and isknownfor its role asa co-stimulatory receptor that
promotes T-cell survival, proliferation, and generation of
memory.5 Specifically, studies inbothhumanandmousemod-
els indicate that CD27 signaling can promote interferon-γ–
dependent immuneresponses,which isparticularlyrelevant for
vitiligo.5,6 Soluble CD27 can be released into the blood circula-
tion by differential splicing and shedding of the extracellular
domain of themembrane-bound receptor on activated T cells.
Interestingly, the serum sCD27 level has been used as a bio-
marker to monitor immune activation and disease burden in
variousinflammatorydisorders;however, it iscurrentlynotclear
whethersCD27hasafunctionalrole intheseconditionsor issim-
ply a by-product of T-cell activation.7,8
Vitiligo is a common T-cell–mediated autoimmune dis-
ease presenting clinically as symmetricalmacular depigmen-
tation caused by epidermal melanocyte loss.9 Recent studies
in vitiligo pathogenesis suggest that targeting functional im-
mune pathwaysmay be an excellent strategy to develop new
treatments.6,10 Randomized clinical trials represent themost
stringent test of efficacy for investigational new drugs. How-
ever, these trials have certain limitations, particularly in re-
gard to the large number of participants needed, the pro-
longed follow-up required to assess the primary study end
point, and the associated costs.11 For vitiligo, time for fol-
low-up is typically 3 to 6months,which canmake trials time-
consuming and expensive.
Adaptive trials have recently garnered attention as an al-
ternative study design because they provide an opportunity
toprospectivelyplanmodifying 1 ormore aspects of the study
design, dependingonan interimanalysis of the results.12 This
may be an optimal early study design, particularly in proof-
of-concept trials, inwhichmany uncertainties about dose re-
sponse, end points, and effect sizes exist.13 Importantly, bio-
marker or surrogate end points are considered a critical
component of adaptive trials because they provide early in-
dication of drug efficacy and enable interim analysis for ad-
aptation of the trial as needed.11 It is therefore crucial to iden-
tify and validate biomarkers that can be used in future trials
to test new investigational drugs in vitiligo.
Another recent study reported that serum levels of the in-
terferon-γ–dependent chemokines CXCL9 and CXCL10 re-
flecteddiseaseactivityandtreatment response invitiligo,14and
the present study now adds additional markers for consider-
ation tobeused in future clinical trials andother clinical stud-
ies.Advantagesof this particular study include the largenum-
berofparticipantsenrolled,allowingsubsetanalysesofdisease
activity and treatment response, aswell as its prospective de-
sign. The authors1 did not find any correlation between se-
rum levels of these soluble molecules and the extent of dis-
ease as definedby the vitiligo body surface area affected. This
is in contrast to a previously published study of sCD25 in a
smaller number of participants.15
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Like many other reports of biomarkers in vitiligo,6,14 1
limitation of this study is that it relies on serum markers
rather than using the tissue directly. Whereas this is more
convenient than obtaining skin biopsies for analysis, these
markers are likely to be present at much lower levels in the
serum than directly in affected tissue, as presumably they
“leak” there from high concentrations in lesional skin and
become diluted. This makes them harder to detect and likely
results in more variability across patients, making it difficult
to set a strict cutoff concentration that is both sensitive and
specific. Importantly, as stated by the authors,1 sCD25 and
sCD27 levels in the serum are not specific to vitiligo but are
elevated in patients with other inflammatory conditions,
including acute and chronic systemic viral infections. Thus,
use of serum biomarkers may be limited to patients with no
other inflammatory conditions, which may be difficult to
determine. Despite these caveats, Speeckaert and colleagues1
provide some important data in a large number of patients
that may translate to useful markers for future clinical trials.
Additional studies of markers in the lesional skin, or poten-
tially combining multiple serum markers, may enhance the
sensitivity and specificity of these assays and provide an
improved strategy to monitor disease activity and treatment
responses in vitiligo.
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